Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CXCR2-transduced autologous tumor infiltrating lymphocytes

A preparation of autologous tumor infiltrating lymphocytes (TILs) that are transduced, ex vivo, with a retroviral vector encoding a gene for CXC chemokine receptor 2 (CXCR2), with potential antineoplastic activity. Upon administration of the CXCR2-transduced autologous TILs, the CXCR2-expressing T cells selectively migrate toward tumor cells expressing CXCR2 ligands, which leads to tumor cell killing. CXCR2 expression allows for optimal TIL migration towards tumor cells and enhances the TILs anti-tumor activity. This leads to a reduction in both tumor cell proliferation and survival. CXCR2, a transmembrane protein also known as IL-8 receptor B (IL-8RB), plays a key role in inflammation and cancer progression. Certain CXCR2 ligands, such as CXCL1 and CXCL8 (IL-8), are expressed by tumor cells.
Synonym:CXCR2-transduced autologous TILs
Search NCI's Drug Dictionary